Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Nxera Pharma UK Limited is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, meaning each case has a unique reviewer. The prosecution is occurring within 2 distinct art units, indicating that the 4 pending office actions are focused on a range of Biotechnology & Pharmaceuticals classifications. This concentration in 2 distinct art units suggests that the company's intellectual property strategy is focused on specific technical niches.
JEAN-LOUIS, SAMIRA JM is identified as the busiest examiner, with 1 busiest examiner pending action currently assigned. Since there are 4 distinct examiners for the 4 pending office actions, the portfolio avoids bottlenecks caused by a reviewer's schedule. The balance of distinct examiners and art units defines the current prosecution landscape for the firm. This distribution allows for separate review paths while maintaining technical focus under JEAN-LOUIS, SAMIRA JM.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JEAN-LOUIS, SAMIRA JM | 1 | 61.0% | +45.2% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258065 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HAVLIN, ROBERT H | 25d overdue |
| 18867575 | CRYSTALLINE FORMS AND SALTS OF A MUSCARINIC RECEPTOR AGONIST | JEAN-LOUIS, SAMIRA JM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258065 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HAVLIN, ROBERT H | 25d overdue |
| 18031416 | LINEAR APELIN RECEPTOR AGONISTS | COFFA, SERGIO | 20d |
| 18867575 | CRYSTALLINE FORMS AND SALTS OF A MUSCARINIC RECEPTOR AGONIST | JEAN-LOUIS, SAMIRA JM | — |
| 18826098 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18867575 | CRYSTALLINE FORMS AND SALTS OF A MUSCARINIC RECEPTOR AGONIST | JEAN-LOUIS, SAMIRA JM | — | §102§112 | Non-Final OA | — | Pending | Nov 20, 2024 |
| 18826098 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | WHITE, DAWANNA SHAR-DAY | — | §103§112DP | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18258065 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HAVLIN, ROBERT H | 1626 | §103§112 | Non-Final OA | 25d overdue | Pending | Jun 16, 2023 |
| 18031416 | LINEAR APELIN RECEPTOR AGONISTS | COFFA, SERGIO | 1658 | §112 | Final Rejection | 20d | Pending | Apr 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial